tbuckley/cabot-search huggingface dataset:
Risk stratification to guide long-term follow up of teenage and young adult survivors of childhood cancer.
Authors: Susannah Jane Stanway, Rachael Windsor, Sarita Depani, Emma Potter, Komel Khabra, Mary Taj
Journal: Journal of Clinical Oncology (2015)

10069 Background: Long term survivors of paediatric cancer have increased over time. Optimal models of long term care must be developed dependent on current and predicted morbidity, which is affected by tumour type and intensity of treatment. Currently, survivors are referred to the long term follow-up (LTFU) clinic 5 years post treatment and are followed indefinately. The aim of this project was to assess use of risk-stratification to guide intensity of LTFU of survivors of childhood cancer. Methods: A retrospective review of the Royal Marsden Hospital Childrens' Late Effects (LE) database was performed. Electronic records of survivors aged 13 to 24 seen in clinic between 2000 to 2012 were reviewed. Patients (pts) were divided into Wallace levels depending on tumour type and treatment given. Number and grades of LEs of treatment were documented using NCI CTC version 4. Results: 316 survivors were divided into Wallace level 1 (n = 18, 6%), 2 (n = 163, 52%) and 3 (n = 135, 43%). At a median follow up of 10.9 years from end of treatment, there were a total of 21 groups of LEs identified. Total LEs were 7 for level 1 pts, 128 for level 2 and 373 for level 3. There were 0.39 LEs seen per pt in level 1, the majority of which were grade 1 or 2, in contrast to 2.72/pt in level 3. The relative risk of at least one grade 3 LE at level 3 compared to level 2 was 4.16. The number lost to follow up was 37, 70% of which were in level 2. Conclusions: All survivors of childhood cancer need a treatment summary and care plan at 5 years post treatment, when the risk of relapse is very small. Stratification using Wallace levels is feasibile and helps define level of care required. Level 1 and 2 pts can be discharged to a primary care colleague informed by a treatment summary and personalised LTFU care plan. Level 3 pts with higher prevalence and grade LEs will need on-going specialist input from a LTFU service.
THU-411-Effectiveness of direct: Acting antivirals for the treatment of viral hepatitis C in Rwanda
Authors: janvier serumondo, michael penkunas, Alida Ngwije, eric remera, Carol Liu, dieudonne sebuhoro, Justine Umutesi, clarisse musanabaganwa, prosper karame, gentille musengimana, corneille killy ntihabose, sabine umuraza, augustin mulindabigwi, julienne niyikora, soline mugeni, Cyprien Ntirenganya, athanase kiromera, Sabin Nsanzimana
Journal: Journal of Hepatology (2019)
Abstract 20531: Ventriculo-Arterial Coupling to Detect Hert Failure Symptoms in Patients With Severe Aortic Regurgitation and Preserved Left Ventricular Ejection Fraction
Authors: Junichi Ooka, Hidekazu Tanaka, Kensuke Matsumoto, Hiroki Takada, Fumitaka Soga, Yutaka Hatani, Keiko Hatazawa, Hiroki Matsuzoe, Hiroyuki Shimoura, Hiroyuki Sano, Yasuhide Mochizuki, Keiko Ryo-Koriyama, Ken-ichi Hirata
Journal: Circulation (2016)

Introduction: Identification of heart failure (HF) symptoms in patients with severe aortic regurgitation (AR) and preserved left ventricular (LV) ejection fraction (EF) is clinically important, but...
ENTPD-1 disrupts inflammasome IL-1β–driven venous thrombosis
Authors: Vinita Yadav, Liguo Chi, Raymond Zhao, Benjamin E. Tourdot, Srilakshmi Yalavarthi, Benjamin N. Jacobs, Alison Banka, Hui Liao, Sharon Koonse, Anuli C. Anyanwu, Scott H. Visovatti, Michael A. Holinstat, J. Michelle Kahlenberg, Jason S. Knight, David J. Pinsky, Yogendra Kanthi
Journal: Journal of Clinical Investigation (2019)

Deep vein thrombosis (DVT), caused by alterations in venous homeostasis is the third most common cause of cardiovascular mortality; however, key molecular determinants in venous thrombosis have not been fully elucidated. Several lines of evidence indicate that DVT occurs at the intersection of dysregulated inflammation and coagulation. The enzyme ectonucleoside tri(di)phosphohydrolase (ENTPD1, also known as CD39) is a vascular ecto-apyrase on the surface of leukocytes and the endothelium that inhibits intravascular inflammation and thrombosis by hydrolysis of phosphodiester bonds from nucleotides released by activated cells. Here, we evaluated the contribution of CD39 to venous thrombosis in a restricted-flow model of murine inferior vena cava stenosis. CD39-deficiency conferred a >2-fold increase in venous thrombogenesis, characterized by increased leukocyte engagement, neutrophil extracellular trap formation, fibrin, and local activation of tissue factor in the thrombotic milieu. This was orchestrated by increased phosphorylation of the p65 subunit of NFκB, activation of the NLRP3 inflammasome, and interleukin-1β (IL-1β) release in CD39-deficient mice. Substantiating these findings, an IL-1β-neutralizing antibody attenuated the thrombosis risk in CD39-deficient mice. These data demonstrate that IL-1β is a key accelerant of venous thrombo-inflammation, which can be suppressed by CD39. CD39 inhibits in vivo crosstalk between inflammation and coagulation pathways, and is a critical vascular checkpoint in venous thrombosis.
THU-048-Intermittent high-flux albumin dialysis with continuous venovenous hemodialysis for acute-on-chronic liver failure and acute kidney injury
Authors: Grzegorz Niewinski, Joanna Raszeja-Wyszomirska, Marta Hrenczuk, Agata Rozga, Piotr Malkowski, Piotr Milkiewicz, Jacek Rozga
Journal: Journal of Hepatology (2019)
Impact of low molecular weight heparin on overall survival in patients with advanced lung cancer: A retrospective study.
Authors: Shuchi Gulati, Mahender Yellu, Nabeela Iffat Siddiqi, Jane M. Pruemer, Changchun Xie, Neetu Radhakrishnan, Nagla Fawzy Abdel Karim
Journal: Journal of Clinical Oncology (2015)

e19150 Background: Low Molecular Heparin (LMWH) is approved for treatment of and secondary prophylaxis against thromboembolic events in patients with cancer. However, its role in improving Overall Survival (OS) remains unclear. We did a retrospective study to evaluate effect of LMWH on OS in advanced lung cancer. Methods: We retrospectively identified patients with advanced lung cancer (stage IIIA, IIIB and IV) including non-small cell, small cell and rare histopathologic subtypes from 2004 to 2014. We excluded patients with early stage lung cancer and those with incomplete information. We collected data on patient demographics (age, gender, ethnicity), histopathology, staging, medications (including chemotherapy and anticoagulants) and patient outcome. Death was considered as the final endpoint. Patients with and without LMWH use were identified. Kaplan-Meier method was used to calculate median OS and 95% CI. Cox model was used to test treatment effect adjusted for age and gender. A subgroup analysis was subsequently performed for patients on LMWH with history of thrombosis to calculate Maximum Likelihood estimates. Data was analyzed using SAS (Ver 9.4). Results: We reviewed 197 patients with advanced lung cancer of which 28 were on LMWH. Their mean age at diagnosis was 62.2 ± 10.8 years. The median OS of the LMWH patients was 460 days (95% CI: 157, 1051) and that of the non LMWH group was 539 days (95% CI: 376, 916), hazard ratio (HR) 1.39 (p = 0.338). The LMWH subgroup with thrombosis (N = 19) had a lower OS (322 days, 95% CI: 157, 1051) compared to the ones without thrombosis. The Maximum Likelihood Estimate for this subgroup after controlling for covariates showed a HR 1.202 (p = 0.751). None of the LMWH patients had a major bleeding event as a cause of death. Conclusions: Our study did not find an improvement in OS with use of LMWH in advanced stage lung cancer patients. Even though the results were not statistically significant, there was a trend towards higher mortality in patients treated with LMWH for thrombosis compared to patients without thrombosis. Future prospective studies using a larger patient population should evaluate the impact of prophylactic versus therapeutic LMWH on OS in advanced lung cancer.
FRI-128-Mesenchymal stem cells cultured in hypoxic conditions had multi-directional effects on mice with liver cirrhosis through prostaglandin E2 and miR210 production
Authors: Atsunori Tsuchiya, Yuichi Kojima, Masahiro Ogawa, Shunsuke Nojiri, Suguru Takauchi, Takayuki Watanabe, Hiroteru Kamimura, Masaaki Takamura, Shuji Terai
Journal: Journal of Hepatology (2019)
FRI-113-Matrix stiffness modulates the phenotype of hepatic cells in cirrhosis and modifies the sinusoidal effects of statins
Authors: Sergi Guixé-Muntet, Marti Ortega-Ribera, Cong Wang, Jaime Bosch, Jean-François Dufour, Annalisa Berzigotti, Jordi Gracia-Sancho
Journal: Journal of Hepatology (2019)
Predicting scheduled hospital attendance with artificial intelligence
Authors: Amy Nelson, Daniel Herron, Geraint Rees, Parashkev Nachev
Journal: npj Digital Medicine (2019)

Failure to attend scheduled hospital appointments disrupts clinical management and consumes resource estimated at £1 billion annually in the United Kingdom National Health Service alone. Accurate stratification of absence risk can maximize the yield of preventative interventions. The wide multiplicity of potential causes, and the poor performance of systems based on simple, linear, low-dimensional models, suggests complex predictive models of attendance are needed. Here, we quantify the effect of using complex, non-linear, high-dimensional models enabled by machine learning. Models systematically varying in complexity based on logistic regression, support vector machines, random forests, AdaBoost, or gradient boosting machines were trained and evaluated on an unselected set of 22,318 consecutive scheduled magnetic resonance imaging appointments at two UCL hospitals. High-dimensional Gradient Boosting Machine-based models achieved the best performance reported in the literature, exhibiting an area under the receiver operating characteristic curve of 0.852 and average precision of 0.511. Optimal predictive performance required 81 variables. Simulations showed net potential benefit across a wide range of attendance characteristics, peaking at £3.15 per appointment at current prevalence and call efficiency. Optimal attendance prediction requires more complex models than have hitherto been applied in the field, reflecting the complex interplay of patient, environmental, and operational causal factors. Far from an exotic luxury, high-dimensional models based on machine learning are likely essential to optimal scheduling amongst other operational aspects of hospital care. High predictive performance is achievable with data from a single institution, obviating the need for aggregating large-scale sensitive data across governance boundaries.
THU-387-Eliminating viral hepatitis C in Belgium: A mathematical model of the micro-elimination approach
Authors: Dana Busschots, Samira Toghanian, Rob Bielen, Stina Salomonsson, Ozgür Koc, Greet Hendrickx, Michel Jadoul, Frederik Nevens, Etienne Sokal, Christian Brixko, Kathelijne Peerlinck, Ludwig Apers, Geert Robaeys, Jeffrey Lazarus
Journal: Journal of Hepatology (2019)
Risk factors for death and survival in paraneoplastic pemphigus associated with hematologic malignancies in adults
Authors: Elise Ouedraogo, Jeremy Gottlieb, Adèle de Masson, Clémence Lepelletier, Marie Jachiet, Camille Salle de Chou, Lionel Galicier, Martine Bagot, Sylvie Chevret, Jean-David Bouaziz
Journal: Journal of the American Academy of Dermatology (2019)
Exhaled Volatile Organic Compounds Are Able to Discriminate between Neutrophilic and Eosinophilic Asthma
Authors: Florence N. Schleich, Delphine Zanella, Pierre-Hugues Stefanuto, Kirill Bessonov, Agnieska Smolinska, Jan W. Dallinga, Monique Henket, Virginie Paulus, Françoise Guissard, Sophie Graff, Catherine Moermans, Emiel F. M. Wouters, Kristel Van Steen, Frederik-Jan van Schooten, Jean-François Focant, Renaud Louis
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

Rationale: Analysis of exhaled breath for asthma phenotyping using endogenously generated volatile organic compounds (VOCs) offers the possibility of noninvasive diagnosis and therapeutic monitoring. Induced sputum is indeed not widely available and markers of neutrophilic asthma are still lacking.Objectives: To determine whether analysis of exhaled breath using endogenously generated VOCs can be a surrogate marker for recognition of sputum inflammatory phenotypes.Methods: We conducted a prospective study on 521 patients with asthma recruited from the University Asthma Clinic of Liege. Patients underwent VOC measurement, fraction of exhaled nitric oxide (FeNO) spirometry, sputum induction, and gave a blood sample. Subjects with asthma were classified in three inflammatory phenotypes according to their sputum granulocytic cell count.Measurements and Main Results: In the discovery study, seven potential biomarkers were highlighted by gas chromatography-mass spectrometry in a training cohort of 276 patients with asthma. In the replication study (n = 245), we confirmed four VOCs of interest to discriminate among asthma inflammatory phenotypes using comprehensive two-dimensional gas chromatography coupled to high-resolution time-of-flight mass spectrometry. Hexane and 2-hexanone were identified as compounds with the highest classification performance in eosinophilic asthma with accuracy comparable to that of blood eosinophils and FeNO. Moreover, the combination of FeNO, blood eosinophils, and VOCs gave a very good prediction of eosinophilic asthma (area under the receiver operating characteristic curve, 0.9). For neutrophilic asthma, the combination of nonanal, 1-propanol, and hexane had a classification performance similar to FeNO or blood eosinophils in eosinophilic asthma. Those compounds were found in higher levels in neutrophilic asthma.Conclusions: Our study is the first attempt to characterize VOCs according to sputum granulocytic profile in a large population of patients with asthma and provide surrogate markers for neutrophilic asthma.
SAT-028-Diabetes is associated with TIPS failure in cirrhotic patients with refractory ascites
Authors: Stella De Nicola, Aldo Airoldi, Giovanni Perricone, Marcello Vangeli, Raffaella Viganò, Marco Solcia, Fabiane Barbosa, Ruggero Vercelli, Carmelo Migliorisi, Antonio Rampoldi, Luca Saverio Belli
Journal: Journal of Hepatology (2019)
Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria
Authors: Martin Greco, María Jesus García de Yébenes, Inmaculada Alarcón, Anahy María Brandy-García, Íñigo Rúa-Figueroa, Estibaliz Loza, Loreto Carmona
Journal: Annals of the Rheumatic Diseases (2019)

The presence of muscle weakness and anti-Jo1 anti-aminoacyl transfer RNA synthetase (ARS) autoantibodies are evaluated in the new European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) proposed classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIM), as well as in the Solomon proposed criteria for antisynthetase syndrome (ASSD) diagnosis.1 2 That favours an overlapping in both criteria fulfilment; however, ASSD is not considered among the IIM subgroups classification.

Anti-Jo1 ARS positivity is the highest weighted criterion in the EULAR/ACR criteria. Furthermore, anti-PL7 and anti-PL12 ARS were found to be strongly associated with IIM during the criteria development; however, the low number of observations limited their reliability analysis, and they were not finally included.1 3 Anti-EJ, anti-OJ and other ARS were not considered at all due to the limited availability of detection methods at the start of the criteria development.3 On the other hand, any ARS positivity is considered in Solomon’s criteria.

Thus, according to other authors, we purpose that IIM and ASSD classification criteria …
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis
Authors: Lenore Buckley, Gordon Guyatt, Howard A. Fink, Michael Cannon, Jennifer Grossman, Karen E. Hansen, Mary Beth Humphrey, Nancy E. Lane, Marina Magrey, Marc Miller, Lake Morrison, Madhumathi Rao, Angela Byun Robinson, Sumona Saha, Susan Wolver, Raveendhara R. Bannuru, Elizaveta Vaysbrot, Mikala Osani, Marat Turgunbaev, Amy S. Miller, Timothy McAlindon
Journal: Arthritis & Rheumatology (2017)

Objective To develop recommendations for prevention and treatment of glucocorticoid‐induced osteoporosis (GIOP). Methods We conducted a systematic review to synthesize the evidence for the benefits and harms of GIOP prevention and treatment options. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence. We used a group consensus process to determine the final recommendations and grade their strength. The guideline addresses initial assessment and reassessment in patients beginning or continuing long‐term (≥3 months) glucocorticoid (GC) treatment, as well as the relative benefits and harms of lifestyle modification and of calcium, vitamin D, bisphosphonate, raloxifene, teriparatide, and denosumab treatment in the general adult population receiving long‐term GC treatment, as well as in special populations of long‐term GC users. Results Because of limited evidence regarding the benefits and harms of interventions in GC users, most recommendations in this guideline are conditional (uncertain balance between benefits and harms). Recommendations include treating only with calcium and vitamin D in adults at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication (oral bisphosphonate preferred) in adults at moderate‐to‐high fracture risk, continuing calcium plus vitamin D but switching from an oral bisphosphonate to another antifracture medication in adults in whom oral bisphosphonate treatment is not appropriate, and continuing oral bisphosphonate treatment or switching to another antifracture medication in adults who complete a planned oral bisphosphonate regimen but continue to receive GC treatment. Recommendations for special populations, including children, people with organ transplants, women of childbearing potential, and people receiving very high‐dose GC treatment, are also made. Conclusion This guideline provides direction for clinicians and patients making treatment decisions. Clinicians and patients should use a shared decision‐making process that accounts for patients’ values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.
SAT-429-Von Willebrand factor a non-invasive serum biomarker of portal pressure in cirrhosis: Evidence in human and rodent
Authors: Xiaolong Qi, Wenda Li, Pinzhu Huang, Xinlong Lin, Xiangbo Zeng, Yanna Liu, Ruizhao Qi, Fuquan Liu, Yu Wang, Chunqing Zhang, Popov Yury
Journal: Journal of Hepatology (2019)
Can basal neutrophil/ lymphocytes ratio predict clinical outcome of melanoma patients?
Authors: Ibrahim Vedat Bayoglu, Gozde Kurtel, Ahmet Alacacioglu, Ceyhun Varim, Ibrahim Yildiz, Yuksel Kucukzeybek, Ahmet Dirican, Lutfiye Demir, Yasar Yildiz, Murat Akyol, Mustafa Oktay Tarhan
Journal: Journal of Clinical Oncology (2015)

e20108 Background: Melanoma is a malignant skin tumor and immune system could play an effective role on clinical outcome of the patients. Sometimes spontaneous remissions could be occur due to immunity. Neutrophil-to-lymphocyte ratio (NLR) may be considered as an indirect indicator for the immune response against to the tumor. In this study, we aimed to evaluate the prognostic importance of basal NLR in patients with melanoma. Methods: Between December 2006 and December 2014, 134 patients with melanoma were retrospectively reviewed and 94 patients were included in our study. The values of NLR were assessed at the time of diagnosis with the hemogram. NLR cut off value was determined as 2,1 by ROC curve. All patients were classified as high and low, according to the cutoff value of NLR 2.1,and statistical analysis was performed. The prognostic significance of NLR on clinical outcome was evaluated with adjustment for known confounding risk factors. Results: Among 94 patients, 37 were metastatic at the time of diagnosis and 57 were received adjuvant interferon-based therapy. When we analysis all cases, median overall survival (OS) were 83.8 months in NLR low group and 23.8 months in NLR high group ( p < 0.001), respectively. For non-metastatic subgroup, median OS were 70,3 months and 40,2 months (p < 0.05), median disease free survival (DFS) were 60.8 months and 14,4 months (p < 0.05) in NLR low and high group respectively. There were no correlation between basal NLR and tumor or patient' characteristics except of a higher NLR ratio was found in patients age > 60 (p = 0.027). Furthermore in univariate analysis, nodal status, ulceration, breslow thickness, tumor T stage and basal NLR were significantly associated with OS and DFS in patients without metastasis. Conclusions: NLR is acceptable for showing the immune response indirectly against to the tumor cells and basal NLR was determined to be an effective significant prognostic factor for median OS and median DFS in melanoma patients. As a result, high basal NLR demonstrated a strong association with worse prognosis in metastatic and non-metastatic melanoma patients and it can be used as a sign for prognosis.
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Authors: Jeff P. Sharman, Steven E. Coutre, Richard R. Furman, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Eugen Tausch, Paula Cramer, Julie Huang, Siddhartha Mitra, Michael Hallek, Susan M. O’Brien, Stephan Stilgenbauer
Journal: Journal of Clinical Oncology (2019)

A randomized, double-blind, phase III study of idelalisib (IDELA) plus rituximab versus placebo plus rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) was terminated early because of superior efficacy of the IDELA-plus-rituximab (IDELA/R) arm. Patients in either arm could then enroll in an extension study to receive IDELA monotherapy. Here, we report the long-term efficacy and safety data for IDELA-treated patients across the primary and extension studies.Patients were randomly assigned to receive rituximab in combination with either IDELA 150 mg twice daily (IDELA/R; n = 110) or placebo (placebo/R; n = 110). Key end points were progression-free survival (PFS), overall response rate (ORR), overall survival (OS), and safety.The long-term efficacy and safety of treatment with IDELA was assessed in 110 patients who received at least one dose of IDELA in the primary study, 75 of whom enrolled in the extension study. The IDELA/R-to-IDELA group had a median PFS of 20.3 months (95% CI, 17.3 to 26.3 months) after a median follow-up time of 18 months (range, 0.3 to 67.6 months). The ORR was 85.5% (94 of 110 patients; n = 1 complete response). The median OS was 40.6 months (95% CI, 28.5 to 57.3 months) and 34.6 months (95% CI, 16.0 months to not reached) for patients randomly assigned to the IDELA/R and placebo/R groups, respectively. Prolonged exposure to IDELA increased the incidence of all-grade, grade 2, and grade 3 or greater diarrhea (46.4%, 17.3%, and 16.4%, respectively), all-grade and grade 3 or greater colitis (10.9% and 8.2%, respectively) and all-grade and grade 3 or greater pneumonitis (10.0% and 6.4%, respectively) but did not increase the incidence of elevated hepatic aminotransferases.IDELA improved PFS and OS compared with rituximab alone in patients with relapsed CLL. Long-term IDELA was effective and had an expected safety profile. No new IDELA-related adverse events were identified with longer exposure.